arrow
J

Justin A. Budka

kite a gilead company
H指数:12
被引数:683

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Determinants of response to CAR T cell therapy in a multicenter, multi-trial cohort analysis of patients with lymphoma

在淋巴瘤患者的多中心,多试验队列分析中对CAR T细胞治疗反应的决定因素

2026-10-230
OAAI
Genomic correlates of clinical CAR T cell activity

临床CAR T细胞活性的基因组相关性

2026-07-240
PRE
Corrigendum to ’In Vitro and In Vivo Characterization of Axicabtagene Ciloleucel Identifies Features Associated with Treatment Resistance in Patients, Including a Dysfunctional CD8+ T Cell State Characterized By Overexpression of GATA3 Transcript’ Transplantation and Cellular Therapy Volume 31 (2025), Issue 2, Supplement, S57

勘误表:‘体内外研究表征axicabtagene ciloleucel,确定了与患者治疗抵抗相关的特征,包括由GATA3转录本过表达表征的功能失调的CD8+ T细胞状态’移植与细胞治疗 卷31(2025),第2期,增刊,S57

2026-04-230
PRE
Tumor gene expression signatures associated with outcome in large B-cell lymphoma treated with CD19-directed CAR T-cell therapy (axicabtagene ciloleucel)

与CD19-directed CAR T细胞疗法 (axicabtagene ciloleucel) 治疗的大b细胞淋巴瘤的预后相关的肿瘤基因表达特征

2025-02-270
OAAI
Impact of Inflammation, Tumor and Product Attributes on Clinical Outcomes in Patients with Relapsed/Refractory Follicular Treated with Ciloleucel

炎症、肿瘤和产品属性对接受Ciloleucel治疗的复发/难治性滤泡性淋巴瘤患者临床结局的影响

BLOOD
IF23.1
2024-11-050
PRE
IL-4 drives exhaustion of CD8+ CART cells

IL-4驱动CD8 CART细胞耗尽

2024-09-120
OAAI
IL-4 drives CART cell exhaustion in a CD4 independent manner
2024-03-220
PRE
Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma

肿瘤微环境对大b细胞淋巴瘤anti-CD19 CAR T细胞治疗或化疗及移植疗效的影响

2024-01-1721
OAAI
Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)
2023-11-179
OAAI
EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming
2017-11-3065
OAAI